{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:15:32Z","timestamp":1777605332609,"version":"3.51.4"},"reference-count":101,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"UNICEF and Alwaleed Philanthropies","award":["43317323"],"award-info":[{"award-number":["43317323"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Measles and rubella micro-array patches (MR-MAPs) are a promising innovation to address limitations of the current needle and syringe (N&amp;S) presentation due to their single-dose presentation, ease of use, and improved thermostability. To direct and accelerate further research and interventions, an initial full value vaccine assessment (iFVVA) was initiated prior to MR-MAPs entering phase I trials to quantify their value and identify key data gaps and challenges. The iFVVA utilized a mixed-methods approach with rapid assessment of literature, stakeholder interviews and surveys, and quantitative data analyses to (i) assess global need for improved MR vaccines and how MR-MAPs could address MR problem statements; (ii) estimate costs and benefits of MR-MAPs; (iii) identify the best pathway from development to delivery; and (iv) identify outstanding areas of need where stakeholder intervention can be helpful. These analyses found that if MR-MAPs are broadly deployed, they can potentially reach an additional 80 million children compared to the N&amp;S presentation between 2030\u20132040. MR-MAPs can avert up to 37 million measles cases, 400,000 measles deaths, and 26 million disability-adjusted life years (DALYs). MR-MAPs with the most optimal product characteristics of low price, controlled temperature chain (CTC) properties, and small cold chain volumes were shown to be cost saving for routine immunization (RI) in low- and middle-income countries (LMICs) compared to N&amp;S. Uncertainties about price and future vaccine coverage impact the potential cost-effectiveness of introducing MR-MAPs in LMICs, indicating that it could be cost-effective in 16\u201381% of LMICs. Furthermore, this iFVVA highlighted the importance of upfront donor investment in manufacturing set-up and clinical studies and the critical influence of an appropriate price to ensure country and manufacturer financial sustainability. To ensure that MR-MAPs achieve the greatest public health benefit, MAP developers, vaccine manufacturers, donors, financiers, and policy- and decision-makers will need close collaboration and open communications.<\/jats:p>","DOI":"10.3390\/vaccines12091075","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T08:12:27Z","timestamp":1726733547000},"page":"1075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["An Application of an Initial Full Value of Vaccine Assessment Methodology to Measles-Rubella MAPs for Use in Low- and Middle-Income Countries"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2695-1547","authenticated-orcid":false,"given":"Melissa","family":"Ko","sequence":"first","affiliation":[{"name":"MMGH Consulting GmbH, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-5429","authenticated-orcid":false,"given":"Collrane","family":"Frivold","sequence":"additional","affiliation":[{"name":"PATH, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7711-9558","authenticated-orcid":false,"given":"Mercy","family":"Mvundura","sequence":"additional","affiliation":[{"name":"PATH, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Soble","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gregory","sequence":"additional","affiliation":[{"name":"UNICEF, New York, NY 10038, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Christiansen","sequence":"additional","affiliation":[{"name":"UNICEF, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-4685","authenticated-orcid":false,"given":"Mateusz","family":"Hasso-Agopsowicz","sequence":"additional","affiliation":[{"name":"World Health Organization, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Fu","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK"},{"name":"School of Public Health, The University of Hong Kong, Hong Kong SAR 999077, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Hsu","sequence":"additional","affiliation":[{"name":"PATH, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-278X","authenticated-orcid":false,"given":"Jessica Joyce","family":"Mistilis","sequence":"additional","affiliation":[{"name":"PATH, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Scarna","sequence":"additional","affiliation":[{"name":"Gavi, The Vaccine Alliance, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Earle","sequence":"additional","affiliation":[{"name":"The Bill and Melinda Gates Foundation, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Menozzi-Arnaud","sequence":"additional","affiliation":[{"name":"Gavi, The Vaccine Alliance, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgitte","family":"Giersing","sequence":"additional","affiliation":[{"name":"World Health Organization, 1211 Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-6891","authenticated-orcid":false,"given":"Courtney","family":"Jarrahian","sequence":"additional","affiliation":[{"name":"PATH, Seattle, WA 98121, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmadu","family":"Yakubu","sequence":"additional","affiliation":[{"name":"UNICEF, New York, NY 10038, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0146-1127","authenticated-orcid":false,"given":"Stefano","family":"Malvolti","sequence":"additional","affiliation":[{"name":"MMGH Consulting GmbH, 8049 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Amorij","sequence":"additional","affiliation":[{"name":"UNICEF, 2100 Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.15585\/mmwr.mm7246a3","article-title":"Progress toward Measles Elimination\u2014Worldwide, 2000\u20132022","volume":"72","author":"Minta","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijid.2023.09.003","article-title":"Estimates of the global burden of Congenital Rubella Syndrome, 1996\u20132019","volume":"137","author":"Vynnycky","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_3","unstructured":"World Health Organization (2024, July 23). WHO\/UNICEF Immunization Coverage Estimates\u20142023 Revision, Available online: https:\/\/www.who.int\/publications\/m\/item\/WUENIC_notes."},{"key":"ref_4","unstructured":"World Health Organization (2024, July 16). Global Measles Threat Continues to Grow as Another Year Passes with Millions of Children Unvaccinated, Available online: https:\/\/www.who.int\/news\/item\/16-11-2023-global-measles-threat-continues-to-grow-as-another-year-passes-with-millions-of-children-unvaccinated."},{"key":"ref_5","unstructured":"Gharib, M. (2017). A Botched Vaccine Campaign For Measles Killed 15 Children in South Sudan, NPR. Available online: https:\/\/www.npr.org\/sections\/goatsandsoda\/2017\/06\/02\/531268150\/a-botched-vaccine-campaign-for-measles-killed-15-children-in-south-sudan."},{"key":"ref_6","unstructured":"Hanson, A., Shah, N., and Cohen, M.R. (2020). Serious Errors with Two-Component Vaccines Risk Harm and Damage Trust, Uppsala Reports. Available online: https:\/\/uppsalareports.org\/articles\/serious-errors-with-two-component-vaccines-risk-harm-and-damage-trust\/."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lee, Y.H., Harris, R.C., Oh, H.W., Oh, Y., Vargas-Zambrano, J.C., and Choe, Y.J. (2021). Vaccine-Related Errors in Reconstitution in South Korea: A National Physicians\u2019 and Nurses\u2019 Survey. Vaccines, 9.","DOI":"10.3390\/vaccines9020117"},{"key":"ref_8","unstructured":"World Health Organization (2024, July 23). WHO Policy Statement: Multi-Dose Vials Policy (MDVP), Revision 2014, Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/135972\/WHO_IVB_14.07_eng.pdf."},{"key":"ref_9","unstructured":"UNICEF (2024, July 23). MR Vaccine, Vial of 10 Doses. Available online: https:\/\/supply.unicef.org\/s359348.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.1016\/j.vaccine.2019.02.079","article-title":"End-user acceptability study of the nanopatchTM; a microarray patch (MAP) for child immunization in low and middle-income countries","volume":"37","author":"Guillermet","year":"2019","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1016\/j.vaccine.2012.09.062","article-title":"Measles vaccination using a microneedle patch","volume":"31","author":"Edens","year":"2013","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.11604\/pamj.supp.2020.35.1.19753","article-title":"Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa","volume":"35","author":"Richardson","year":"2020","journal-title":"Pan Afr. Med. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e012247","DOI":"10.1136\/bmjgh-2023-012247","article-title":"Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: A systematic review and meta-analysis","volume":"8","author":"Berger","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hasso-Agopsowicz, M., Crowcroft, N., Biellik, R., Gregory, C.J., Menozzi-Arnaud, M., Amorij, J.-P., Gilbert, P.-A., Earle, K., Frivold, C., and Jarrahian, C. (2022). Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.809675"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1016\/j.vaccine.2019.03.035","article-title":"Potential use of microarray patches for vaccine delivery in low- and middle-income countries","volume":"37","author":"Peyraud","year":"2019","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1080\/14760584.2023.2270598","article-title":"Microarray patches: Scratching the surface of vaccine delivery","volume":"22","author":"Choo","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ko, M., Malvolti, S., Cherian, T., Mantel, C., Biellik, R., Jarrahian, C., Menozzi-Arnaud, M., Amorij, J.-P., Christiansen, H., and Papania, M.J. (2023). Estimating the future global dose demand for measles\u2013rubella microarray patches. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1037157"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Malvolti, S., Ko, M., Menozzi-Arnaud, M., Mantel, C., Jarrahian, C., Amorij, J.-P., Giersing, B., and Hasso-Agopsowicz, M. (2023). Exploring potential applications of measles and rubella microarray patches (MR-MAPs): Use case identification. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1165110"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.vaccine.2023.12.047","article-title":"A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches","volume":"42","author":"Soble","year":"2024","journal-title":"Vaccine"},{"key":"ref_20","unstructured":"PATH Microarray Patch Center of Excellence (2021). Measles-Rubella Microarray Patch Vaccines: A Business Case Analysis, Linksbridge SPC. Available online: https:\/\/www.path.org\/our-impact\/resources\/microarray-patch-business-cases\/."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Trotter, C., Giersing, B., Lindstrand, A., Bar-Zeev, N., Cernuschi, T., Franzel-Sassanpour, L., Friede, M., Hombach, J., Jansen, M., and Hasso-Agopsowicz, M. (2024). A Practical Guide to Full Value of Vaccine Assessments. Vaccines, 12.","DOI":"10.3390\/vaccines12020201"},{"key":"ref_22","unstructured":"(2024, July 23). Vaccine Innovation Prioritisation Strategy. Available online: https:\/\/www.gavi.org\/our-alliance\/market-shaping\/vaccine-innovation-prioritisation-strategy."},{"key":"ref_23","unstructured":"Gavi, the Vaccine Alliance (2021). Vaccine Microarray Patches (MAPs): Public Summary of the VIPS Alliance Action Plan, UNICEF. Available online: https:\/\/www.gavi.org\/sites\/default\/files\/about\/market-shaping\/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1016\/j.vaccine.2021.05.102","article-title":"A global collaboration to advance vaccine product innovations\u2014The Vaccine Innovation Prioritisation Strategy","volume":"39","author":"Kristensen","year":"2021","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/17425247.2023.2168641","article-title":"Accelerating the development of vaccine microarray patches for epidemic response and equitable immunization coverage requires investment in microarray patch manufacturing facilities","volume":"20","author":"Friede","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1016\/j.vaccine.2021.08.024","article-title":"Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations","volume":"39","author":"Mvundura","year":"2021","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1016\/j.vaccine.2021.07.091","article-title":"Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries","volume":"39","author":"Giersing","year":"2021","journal-title":"Vaccine"},{"key":"ref_28","unstructured":"World Health Organization, and United Nations Children\u2019s Fund (UNICEF) (2024, July 23). Measles-Rubella Microarray Patch (MR\u2013MAP) Target Product Profile, Available online: https:\/\/iris.who.int\/handle\/10665\/330394."},{"key":"ref_29","unstructured":"World Health Organization (2024, July 23). MI4A Vaccine Purchase Data, Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/vaccine-access\/mi4a\/mi4a-vaccine-purchase-data."},{"key":"ref_30","unstructured":"UNICEF (2021). Vaccines Pricing Data, UNICEF. Available online: https:\/\/www.unicef.org\/supply\/vaccines-pricing-data."},{"key":"ref_31","unstructured":"Pan American Health Organization PAHO (2021). Revolving Fund Vaccine Prices for 2021\u2014PAHO\/WHO, PAHO. Available online: https:\/\/www.paho.org\/en\/documents\/paho-revolving-fund-vaccine-prices-2021."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1016\/j.vaccine.2017.04.063","article-title":"Challenges of vaccine presentation and delivery: How can we design vaccines to have optimal programmatic impact?","volume":"35","author":"Giersing","year":"2017","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100032","DOI":"10.1016\/j.jvacx.2019.100032","article-title":"Evaluating the cost per child vaccinated with full versus fractional-dose inactivated poliovirus vaccine","volume":"2","author":"Mvundura","year":"2019","journal-title":"Vaccine X"},{"key":"ref_34","unstructured":"World Health Organization (2024, July 23). Revising Global Indicative Wastage Rates: A WHO Initiative for Better Planning and Forecasting of Vaccine Supply Needs, Available online: https:\/\/www.who.int\/docs\/default-source\/immunization\/tools\/revising-wastage-concept-note.pdf?sfvrsn=30e43557_4."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Gandhi, G., and Lydon, P. (2014). Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts. BMC Public Health, 14.","DOI":"10.1186\/1471-2458-14-67"},{"key":"ref_36","unstructured":"World Health Organization (2024, July 23). Controlled Temperature Chain (CTC), Available online: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/essential-programme-on-immunization\/supply-chain\/controlled-temperature-chain-(ctc)."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e012204","DOI":"10.1136\/bmjgh-2023-012204","article-title":"Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: Mathematical modelling and early-stage economic evaluation","volume":"8","author":"Fu","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"G\u00f6tze, U., Northcott, D., and Schuster, P. (2015). Discounted Cash Flow Methods. Investment Appraisal, Springer. Available online: https:\/\/link.springer.com\/10.1007\/978-3-662-45851-8_3.","DOI":"10.1007\/978-3-662-45851-8_3"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e1664","DOI":"10.1016\/S2214-109X(19)30439-5","article-title":"Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: A modelling study","volume":"7","author":"Debellut","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_40","unstructured":"Gavi, the Vaccine Alliance (2018). Vaccine Investment Strategy 2018, Gavi, the Vaccine Alliance. Available online: https:\/\/www.gavi.org\/our-alliance\/strategy\/vaccine-investment-strategy-2018."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Baker, B., Bermingham, I.M., Leelasena, I., Hickling, J., Young, P.R., Muller, D.A., and Forster, A.H. (2023). Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial. Vaccines, 11.","DOI":"10.20944\/preprints202308.0501.v1"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","article-title":"A measles and rubella vaccine microneedle patch in The Gambia: A phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial","volume":"403","author":"Adigweme","year":"2024","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev-chembioeng-060816-101514","article-title":"Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin","volume":"8","author":"Prausnitz","year":"2017","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"ref_45","unstructured":"(2024, August 01). Technical Advisory Group on Measles and Rubella Microarray Patches (MR-MAPs). Available online: https:\/\/www.who.int\/news-room\/articles-detail\/2023-November-132."},{"key":"ref_46","unstructured":"PATH (2014). Pentavalent Vaccine in the Uniject Injection System: A Time and Motion Study, PATH."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1016\/j.vaccine.2014.10.063","article-title":"A systematic literature review of missed opportunities for immunization in low- and middle-income countries","volume":"32","author":"Sridhar","year":"2014","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tabatabaei, S.M., Khorashad, A.S., Shahraki, S., and Elhami, F.M. (2017). A Study on Bacterial Contamination of Multidose Vaccine Vials in Southeast of Iran. Int. J. Infect., 4.","DOI":"10.5812\/iji.62887"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/heapro\/dah110","article-title":"Unsafe injections in low-income country health settings: Need for injection safety promotion to prevent the spread of blood-borne viruses","volume":"19","author":"Kermode","year":"2004","journal-title":"Health Promot. Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"P\u00e9pin, J., Chakra, C.N.A., P\u00e9pin, E., Nault, V., and Valiquette, L. (2014). Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000\u20132010. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099677"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Mantel, C., Khamassi, S., Baradei, K., Nasri, H., Mohsni, E., and Duclos, P. (2007). Improved injection safety after targeted interventions in the Syrian Arab Republic. Trop. Med. Int. Health.","DOI":"10.1111\/j.1365-3156.2007.01802.x"},{"key":"ref_52","first-page":"683","article-title":"Management of Needlestick Injuries in the Health Care Setting","volume":"7","author":"Penalver","year":"2005","journal-title":"AMA J. Ethic-"},{"key":"ref_53","first-page":"41","article-title":"Needlestick\/sharps injuries and HIV exposure among health care workers. National estimates based on a survey of U.S. hospitals","volume":"78","author":"Henry","year":"1995","journal-title":"Minn. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2471\/BLT.11.094029","article-title":"Integrating pneumonia prevention and treatment interventions with immunization services in resource-poor countries","volume":"90","author":"Cohen","year":"2012","journal-title":"Bull. World Health Organ."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-3156.2008.02196.x","article-title":"Integration of immunization services with other health interventions in the developing world: What works and why? Systematic literature review","volume":"14","author":"Wallace","year":"2009","journal-title":"Trop. Med. Int. Health"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00103-019-03066-x","article-title":"New immunization strategies: Adapting to global challenges","volume":"63","author":"Mantel","year":"2019","journal-title":"Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz"},{"key":"ref_57","first-page":"726","article-title":"Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries","volume":"81","author":"Drain","year":"2003","journal-title":"Bull. World Health Organ."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2020.07.012","article-title":"The effects of switching from 10 to 5-dose vials of MR vaccine on vaccination coverage and wastage: A mixed-method study in Zambia","volume":"38","author":"Krudwig","year":"2020","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1016\/j.vaccine.2018.06.009","article-title":"Assessment of vaccine wastage rates, missed opportunities, and related knowledge, attitudes and practices during introduction of a second dose of measles-containing vaccine into Cambodia\u2019s national immunization program","volume":"36","author":"Wallace","year":"2018","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1016\/j.vaccine.2017.09.082","article-title":"Vaccine wastage in Nigeria: An assessment of wastage rates and related vaccinator knowledge, attitudes and practices","volume":"35","author":"Wallace","year":"2017","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.vaccine.2018.12.010","article-title":"The value of tailoring vial sizes to populations and locations","volume":"37","author":"Wedlock","year":"2018","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e04016","DOI":"10.1016\/j.heliyon.2020.e04016","article-title":"Estimation of the wastage rate of MMR and pentavalent vaccines in open and closed vials in three western provinces of Iran","volume":"6","author":"Zahraei","year":"2020","journal-title":"Heliyon"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1016\/j.vaccine.2018.04.070","article-title":"Enhancing immunization during second year of life by reducing missed opportunities for vaccinations in 46 countries","volume":"36","author":"Hanson","year":"2018","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1016\/j.vaccine.2019.06.041","article-title":"Opportunities to improve vaccination coverage in a country with a fledgling health system: Findings from an assessment of missed opportunities for vaccination among health center attendees\u2014Timor Leste, 2016","volume":"37","author":"Li","year":"2019","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/gatesopenres.12761.1","article-title":"Reducing missed opportunities for vaccination in selected provinces of Mozambique: A study protocol","volume":"1","author":"Magadzire","year":"2017","journal-title":"Gates Open Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"30963","DOI":"10.3402\/gha.v9.30963","article-title":"Missed opportunities in full immunization coverage: Findings from low- and lower-middle-income countries","volume":"9","author":"Barros","year":"2016","journal-title":"Glob. Health Action"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.29245\/2578-3009\/2018\/si.1107","article-title":"Towards a Strategy for Reducing Missed Opportunities for Vaccination in Malawi: Implications of a Qualitative Health Facility Assessment","volume":"2","author":"Okeibunor","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ogbuanu, I.U., Li, A.J., Anya, B.-P.M., Tamadji, M., Chirwa, G., Chiwaya, K.W., Djalal, M.E.-H., Cheikh, D., Machekanyanga, Z., and Okeibunor, J. (2019). Can vaccination coverage be improved by reducing missed opportunities for vaccination? Findings from assessments in Chad and Malawi using the new WHO methodology. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0210648"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1093\/infdis\/jiu288","article-title":"An Evaluation of Community Perspectives and Contributing Factors to Missed Children During an Oral Polio Vaccination Campaign\u2014Katsina State, Nigeria","volume":"210","author":"Michael","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Li, A.J., Tabu, C., Shendale, S., Sergon, K., Okoth, P.O., Mugoya, I.K., Machekanyanga, Z., Onuekwusi, I.U., Sanderson, C., and Ogbuanu, I.U. (2020). Assessment of missed opportunities for vaccination in Kenyan health facilities, 2016. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237913"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Li, A.J., Tabu, C., Shendale, S., Okoth, P.O., Sergon, K., Maree, E., Mugoya, I.K., Machekanyanga, Z., Onuekwusi, I.U., and Ogbuanu, I.U. (2020). Qualitative insights into reasons for missed opportunities for vaccination in Kenyan health facilities. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230783"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1016\/j.vaccine.2020.10.021","article-title":"Assessment of missed opportunities for vaccination (MOV) in Burkina Faso using the World Health Organization\u2019s revised MOV strategy: Findings and strategic considerations to improve routine childhood immunization coverage","volume":"38","author":"Meda","year":"2020","journal-title":"Vaccine"},{"key":"ref_73","first-page":"549","article-title":"Studies of missed opportunities for immunization in developing and industrialized countries","volume":"71","author":"Hutchins","year":"1993","journal-title":"Bull. World Health Organ."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4721836","DOI":"10.1155\/2016\/4721836","article-title":"Missed Opportunities for Vaccination in the Dominican Republic: Results of an Operational Investigation","volume":"2016","author":"Garib","year":"2016","journal-title":"BioMed Res. Int."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"100005","DOI":"10.1016\/j.joclim.2021.100005","article-title":"Eco-friendly vaccination: Tackling an unforeseen adverse effect","volume":"1","author":"Phadke","year":"2021","journal-title":"J. Clim. Change Health"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6059","DOI":"10.1016\/j.vaccine.2017.09.046","article-title":"A systematic review of factors affecting vaccine uptake in young children","volume":"35","author":"Smith","year":"2017","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-019-7176-4","article-title":"Implementation of the World\u2019s largest measles-rubella mass vaccination campaign in Bangladesh: A process evaluation","volume":"19","author":"Sarma","year":"2019","journal-title":"BMC Public Health"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s13312-015-0580-7","article-title":"Commitment of measles elimination by 2020: Challenges in India","volume":"52","author":"Vaidya","year":"2015","journal-title":"Indian Pediatr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1016\/S0140-6736(16)32217-6","article-title":"Measles vaccination: Global progress, local challenges","volume":"388","author":"Lancet","year":"2016","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.healthpol.2020.02.015","article-title":"Strengthening vaccination programmes and health systems in the European Union: A framework for action","volume":"124","author":"Siciliani","year":"2020","journal-title":"Health Policy"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/10810730.2021.1879366","article-title":"Vaccine Hesitancy and Demand for Immunization in Eastern Europe and Central Asia: Implications for the Region and Beyond","volume":"25","author":"Obregon","year":"2020","journal-title":"J. Health Commun."},{"key":"ref_82","first-page":"291","article-title":"Immunization in Vietnam","volume":"31","author":"Nguyen","year":"2019","journal-title":"Ann. Ig. Med. Prev. Comunit\u00e0"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-020-00302-9","article-title":"Vaccine Hesitancy as a Challenge or Vaccine Confidence as an Opportunity for Childhood Immunisation in India","volume":"9","author":"Agrawal","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27784","DOI":"10.3402\/iee.v5.27784","article-title":"Measles in India: Challenges & recent developments","volume":"5","author":"Shrivastava","year":"2015","journal-title":"Infect. Ecol. Epidemiology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1469-0691.12584","article-title":"The state of measles and rubella in the WHO European Region, 2013","volume":"20","author":"Muscat","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00430-016-0451-4","article-title":"Eradication of measles: Remaining challenges","volume":"205","author":"Holzmann","year":"2016","journal-title":"Med Microbiol. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00103-020-03241-5","article-title":"Die globale Masernkrise\u2014Ursachenvielfalt von bewaffneten Konflikten bis Impfskepsis","volume":"63","author":"Denkel","year":"2020","journal-title":"Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Davis, R., and Mbabazi, W.B. (2017). Challenges to global measles eradication: Is it all in the timing?. Pan Afr. Med J., 27.","DOI":"10.11604\/pamj.supp.2017.27.3.12553"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0033354919826558","article-title":"Measles and the Modern History of Vaccination","volume":"134","author":"Conis","year":"2019","journal-title":"Public Health Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/jpgm.JPGM_166_17","article-title":"Elimination of measles from India","volume":"63","author":"Bavdekar","year":"2017","journal-title":"J. Postgrad. Med."},{"key":"ref_91","first-page":"1","article-title":"The end of measles and congenital rubella: An achievable dream?","volume":"29","author":"Adamo","year":"2017","journal-title":"Ann. Ig. Med. Prev. Comunita"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2018863","DOI":"10.1080\/21645515.2021.2018863","article-title":"Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings","volume":"18","author":"Davies","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4896","DOI":"10.1016\/j.vaccine.2017.07.083","article-title":"Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents","volume":"35","author":"Marshall","year":"2017","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1016\/j.vaccine.2020.07.064","article-title":"Acceptability of an inactivated influenza vaccine delivered by microneedle patch: Results from a phase I clinical trial of safety, reactogenicity, and immunogenicity","volume":"38","author":"Frew","year":"2020","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0140-6736(17)30575-5","article-title":"The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): A randomised, partly blinded, placebo-controlled, phase 1 trial","volume":"390","author":"Rouphael","year":"2017","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0722.2006.00335.x","article-title":"Dental and medical injections: Prevalence of self-reported problems among 18-yr-old subjects in Norway","volume":"114","author":"Vika","year":"2006","journal-title":"Eur. J. Oral Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1016\/j.vaccine.2012.05.011","article-title":"Survey of the prevalence of immunization non-compliance due to needle fears in children and adults","volume":"30","author":"Taddio","year":"2012","journal-title":"Vaccine"},{"key":"ref_98","first-page":"172","article-title":"Fear of needles Nature and prevalence in general practice","volume":"38","author":"Wright","year":"2009","journal-title":"Aust. Fam. Physician"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jan.13818","article-title":"The fear of needles: A systematic review and meta-analysis","volume":"75","author":"McLenon","year":"2018","journal-title":"J. Adv. Nurs."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4269\/ajtmh.2003.68.341","article-title":"Fear of injections in young adults: Prevalence and associations","volume":"68","author":"Nir","year":"2003","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2377960818759442","DOI":"10.1177\/2377960818759442","article-title":"Fear of Injections and Needle Phobia Among Children and Adolescents: An Overview of Psychological, Behavioral, and Contextual Factors","volume":"4","author":"Orenius","year":"2018","journal-title":"SAGE Open Nurs."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:59:39Z","timestamp":1760111979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":101,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12091075"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12091075","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]}}}